The term neurodegeneration describes a broad group of conditions characterized by the progressive loss of nerve cells in specific regions of the brain or spinal cord.<\/p>\n\n\n\n
These conditions include Alzheimer\u2019s disease, the most common cause of dementia, Parkinson\u2019s disease, amyotrophic lateral sclerosis (ALS), Huntington\u2019s disease and other, less common degenerative disorders.<\/p>\n\n\n\n
Despite their varied clinical presentations\u2014cognitive decline in Alzheimer\u2019s disease, movement disorders in Parkinson\u2019s disease and progressive paralysis in ALS\u2014they share several pathophysiological features, including mitochondrial dysfunction, oxidative stress, neuroinflammation and, ultimately, neuronal apoptosis.<\/p>\n\n\n\n
These common mechanisms provide a basis for therapeutic interventions aimed at improving the metabolic environment of nervous tissue.<\/p>\n\n\n\n
Oxidative stress further aggravates this process by damaging proteins, lipids and DNA within nerve cells.<\/p>\n\n\n\n
The central problem in all neurodegenerative conditions is that nerve cells are lost at a rate that exceeds the nervous system\u2019s limited capacity for natural renewal.<\/p>\n\n\n\n
The brain is capable of neurogenesis, meaning the production of new neurons, but to a much lesser extent than other tissues. Preserving the viability of existing neurons is therefore of fundamental importance.<\/p>\n\n\n\n
Mitochondrial dysfunction is a common underlying feature. Mitochondria produce adenosine triphosphate (ATP), the primary source of energy for neurons, but their function is impaired in neurodegenerative diseases. The resulting energy deficit accelerates neuronal degeneration.<\/p>\n\n\n\n
Oxidative stress further aggravates this process by damaging proteins, lipids and DNA within nerve cells.<\/p>\n\n\n\n
Research into the use of hyperbaric oxygen therapy in neurodegenerative conditions is still developing, although experimental and early clinical findings have been encouraging.<\/p>\n\n\n\n
Studies in animal models of Alzheimer\u2019s and Parkinson\u2019s disease have reported reduced accumulation of pathological proteins, improved mitochondrial function and inhibition of neuronal apoptosis.<\/p>\n\n\n\n
Early human studies have also reported improvements in certain cognitive measures among patients with mild cognitive impairment or early-stage Alzheimer\u2019s disease following a course of hyperbaric oxygen therapy.<\/p>\n\n\n\n
The proposed mechanisms of action include improved mitochondrial efficiency through increased oxygenation, reduced oxidative stress through the activation of antioxidant enzymes and stimulation of neurotrophic factors that support neuronal survival.<\/p>\n\n\n\n
The scientific community continues to monitor and evaluate these emerging findings with considerable interest.<\/p>\n\n\n\n
In neurodegenerative conditions, hyperbaric oxygen therapy is used as an adjunctive intervention. It does not replace neurological treatment but aims to improve the metabolic environment in which neurons are attempting to survive.<\/p>\n\n\n\n
Hyperbaric oxygen therapy does not cure neurodegenerative disease, and this distinction must remain clear. However, it may contribute to slowing disease progression and preserving function.<\/p>\n\n\n\n
Improved mitochondrial efficiency through increased oxygenation may provide neurons with the energy required to function and resist degenerative processes. The simultaneous reduction of oxidative stress and neuroinflammation may also address two of the principal mechanisms driving neurodegeneration.<\/p>\n\n\n\n
The treatment course is tailored to the specific condition and its stage and typically consists of 40 to 60 sessions, always in close collaboration with the neurologist.<\/p>\n","protected":false},"excerpt":{"rendered":"
What Is Neurodegeneration? The term neurodegeneration describes a broad group of conditions characterized by the progressive loss of nerve cells in specific regions of the … <\/p>\n